Submit a regular abstract, Young Investigator Award abstract, late-breaking abstract application or Immunotherapy Resistance and Failure Pre-Conference Program presentation application for SITC 2020. All authors of accepted abstracts will have the opportunity to virtually present their research and have it published as a supplement in the Journal for ImmunoTherapy of Cancer (JITC).
SITC Cancer Immunotherapy Guidelines – Free Multiple Myeloma WebinarLearn about SITC’s clinical practice guidelines for immunotherapy for multiple myeloma in this free SITC webinar on Sept. 3, 2020, at 7 p.m. EDT.
The Certificate in Cancer Immunotherapy consists of eight independent learning modules—all approved for CME, CNE, CPE and MOC credits—that can be stacked to earn the SITC Graduate in Cancer Immunotherapy (SITC-G) designation. The SITC-G designation identifies a healthcare provider as completing specialized training in cancer immunotherapy.
SITC's 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) will be reimagined as a fully VIRTUAL experience this year, and in celebration of the society's 35th anniversary, all SITC members are invited to register for FREE!
JITC Increases Impact Factor to 9.913The Journal for ImmunoTherapy of Cancer (JITC), recently received new metrics on citations tabulated in Web of Science and Scopus.
The Society for Immunotherapy of Cancer (SITC) is committed to providing the most current COVID-19 information and resources to its members and the oncology community at large.
Join Mary Disis, MD, FACP, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.
New Online Patient Course Available: Understanding Cancer Immunotherapy Access SITC’s dedicated resource for patients and caregivers to learn about cancer immunotherapy
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
Purpose: Conversations directly relevant to patient care Audience: Practicing clinicians and staff, clinical investigators Suggested topics: demographics, clinical presentation, diagnostic testing, patient management issues/insights, patterns in ...
Purpose: Conversations directly relevant to research Audience: Laboratory and translational scientists Suggested topics: Data sharing, emerging literature, sample/tissue collection, model/reagent development, opportunities for collaboration, translational ...
This comprehensive review outlines some of the immunotherapies that are currently being used to treat COVID-19 patients. Included are details of convalescent plasma therapy, monoclonal antibodies, cytokine therapy, mesenchymal stem cell therapy, intravenous ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org